

S 4134

Increasing Access to Biosimilars Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jul 1, 2020

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Jul 1, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/4134>

Sponsor

Name: Sen. Cornyn, John [R-TX]

Party: Republican • **State:** TX • **Chamber:** Senate

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Bennet, Michael F. [D-CO]	D · CO		Jul 1, 2020
Sen. Smith, Tina [D-MN]	D · MN		Dec 10, 2020

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jul 1, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 6179	Related bill	Mar 10, 2020: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary (as of Jul 1, 2020)

Increasing Access to Biosimilars Act of 2020

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

Actions Timeline

- **Jul 1, 2020:** Introduced in Senate
- **Jul 1, 2020:** Read twice and referred to the Committee on Finance.